| Assessment Status | Rapid Review complete |
| HTA ID | - |
| Drug | Carfilzomib (in combination with dexamethasone) |
| Brand | Kyprolis® |
| Indication | For the treatment of adult patients with multiple myeloma who have received at least one prior therapy |
| Assessment Process | |
| Rapid review commissioned | 11/02/2019 |
| Rapid review completed | 19/03/2019 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of carfilzomib in combination with dexamethasone compared with the current standard of care, on the basis of the proposed price relative to currently available therapies. |
The HSE has approved reimbursement following confidential price negotiations; October 2020
